Objective This work aims to explore whether Toll-like receptor 9 (TLR9) −1486T/C and 2848G/A polymorphisms are associated with cervical cancer risk.
Methods A comprehensive electronic search of studies published from January 1999 to October 2014 was conducted in Medline (Ovid), Embase, PubMed, Wanfang, Weipu, and CNKI. The algorithm included “TLR,” “Toll-like receptor,” “polymorphism,” “variant,” “mutation,” and “cervical cancer.” Seven articles, including 9 studies, were pooled using Revman 5.2 (Cochrane Collaboration, Copenhagen, Denmark). Odds ratio (OR) was used to explore the involvement of minor allele C (C vs T and CC + CT vs TT) of TLR9 (−1486T/C, rs187084) and minor allele A (A vs G and AA + AG vs GG) of TLR9 (2848G/A, rs352140) in cervical cancer risk.
Results Toll-like receptor 9 (−1486T/C, rs187084) polymorphisms were associated with an elevated risk of cervical cancer (C vs T: OR, 1.15; 95% confidence interval [CI], 1.03–1.29; CC + CT vs TT: OR, 1.30; 95% CI, 1.11–1.53). We found no significant association between TLR9 (2848G/A, rs352140) polymorphisms and cervical cancer risk (A vs G: OR, 1.15; 95% CI, 0.87–1.54; AA + AG vs GG: OR, 1.27; 95% CI, 0.75–2.17).
Conclusions This meta-analysis indicates that TLR9 (−1486T/C, rs187084)—but not TLR9 (2848G/A, rs352140)—may be a risk factor for cervical cancer.
- Cervical cancer
- Toll-like receptor
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This work was supported by the National High Technology Research and Development Program of China (Grant No. 2014AA020708) and the China Postdoctoral Science Foundation (Grant No. 20120181110029).
The authors declare no conflicts of interest.